Giulia Sedda

@ieo.it

Department of Thoracic Surgery
European Institute of Oncology



                 

https://researchid.co/giuliasedda
28

Scopus Publications

832

Scholar Citations

10

Scholar h-index

12

Scholar i10-index

Scopus Publications

  • Diagnostic Performance and Cell Count of EBUS–TBNA Needle Gauges: A Prospective Trial
    Juliana Guarize, Cristina Diotti, Monica Casiraghi, Stefano Donghi, Clementina Di Tonno, Patrizia Mancuso, Laura Zorzino, Giulia Sedda, Davide Radice, Luca Bertolaccini,et al.
    MDPI AG
    Background. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a well-established diagnostic procedure for evaluating hilar and mediastinal lymphadenopathies and is the gold standard for lung cancer diagnosis and staging. Recent studies assessed the effectiveness of the 19-G flex needle in obtaining larger EBUS-TBNA samples, and prospective small series gave similar results in terms of diagnostic yield when testing different gauge needles. The lack of homogeneity between series and the small sample size of some prospective cohorts poses a limit to the validity of those results. This prospective controlled study compared the 19-G flex and 22-G needles in terms of diagnostic yield. An objective laboratory method was used to count cells and compare the two needles’ cytologic yields. Material. A prospective controlled study was conducted on 90 patients undergoing EBUS-TBNA for the diagnosis of hilar and mediastinal lymphadenopathies. The institutional ethic committee (IEO573) approved the study, and informed consent was obtained from all patients. Results. A total of 90 patients were enrolled in this study, 84.4% of whom were diagnosed with malignancy and 15.6% with non-neoplastic disease. Sensitivity for malignancy was 93.4% (CI: 87.4–97.1%) for the 19-G needle and 92.6% (CI: 86.3–96.5%) for the 22-G needle (p = 0.80). The percentage of malignant cells in the cell block was 63.9% and 61.5% for the 22-G and 19-G needles, respectively. The cell count assessed by flow cytometry was 2071 cells/µL (IQR: 600,2265) with the 22-G needle and 2761 cells/µL (IQR: 505,3250) with the 19-G needle (p = 0.79). The malignant cell count was 0.05 × 103 cells/µL with the 22-G and 0.08 × 103 cells/µL with the 19-G needle (p = 0.70). There was no difference in the presence of tissue cores in the samples, and rapid on-site evaluation (ROSE) cellularity was comparable between the two needles. Conclusions. The 19-G flex EBUS-TBNA needle is comparable to the 22-G needle in terms of diagnostic yield for cyto-histological evaluation of hilar and mediastinal lymphadenopathies. There is no difference between the 19-G and 22-G needle cell counts evaluated by flow cytometry.

  • The Role of Surgery in Primary Chest Wall Tumors: Over 20 Years’ Experience in Resection and Reconstruction
    Giorgio Lo Iacono, Antonio Mazzella, Shehab Mohamed, Francesco Petrella, Giulia Sedda, Monica Casiraghi, Lara Girelli, Luca Bertolaccini, and Lorenzo Spaggiari
    MDPI AG
    Background: Primary chest wall tumors comprise a heterogeneous group of neoplasms arising from soft tissues and bones. While surgical excision is the standard of care for benign tumors, the management of malignant tumors requires multimodal treatment. We conducted a predictive analysis of outcome, recurrence-free and overall survival. Methods: We retrospectively reviewed the clinical and pathological records of all patients treated in our center between 1998 and 2020. Results: 53 patients (15–85 years) were treated in our department. The average tumor diameter was 65 ± 35 mm (10–160 mm). Negative margins were obtained in 48 patients (90.6%), whereas in the remaining 5, R1 resection was accomplished. Median overall survival was 63,03 months (1–282 months). Overall survival was 90% at 1 year, 78% at 2 years, and 61% at 5 years. Our analysis identified tumor diameter, postoperative complications, and high grade of malignancy as factors that can influence prognosis. Conclusions: The treatment of primary chest wall tumors remains a very challenging process. Different histological types preclude definition of an unequivocal approach. Complete resection with healthy margins remains a definitive cornerstone in the treatment of these cancers as part of a more comprehensive approach.

  • Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study
    Monica Casiraghi, Francesco Petrella, Claudia Bardoni, Shehab Mohamed, Giulia Sedda, Juliana Guarize, Antonio Passaro, Filippo De Marinis, Patrick Maisonneuve, and Lorenzo Spaggiari
    MDPI AG
    Introduction The suitability of adjuvant therapy (AT) in patients with stage IB non-small cell lung cancer (NSCLC) is still under debate considering the cost–benefit ratio between improvement in survival and side effects. We retrospectively evaluated survival and incidence of recurrence in radically resected stage IB NSCLC, to determine whether AT could significantly improve prognosis. Methods Between 1998 and 2020, 4692 consecutive patients underwent lobectomy and systematic lymphadenectomy for NSCLC. Two hundred nineteen patients were pathological T2aN0M0 (>3 and ≤4 cm) NSCLC 8th TNM. None received preoperative or AT. Overall survival (OS), cancer specific survival (CSS) and the cumulative incidence of relapse were plotted and log-rank or Gray’s tests were used to assess the difference in outcome between groups. Results The most frequent histology was adenocarcinoma (66.7%). Median OS was 146 months. The 5-, 10-, and 15-year OS rates were 79%, 60%, and 47%, whereas the 5-, 10-, and 15-year CSS were 88%, 85%, and 83%, respectively. OS was significantly related to age (p < 0.001) and cardiovascular comorbidities (p = 0.04), whereas number of LNs removed was an independent prognostic factor of CSS (p = 0.02). Cumulative incidence of relapse at 5-, 10-, and 15-year were 23%, 31%, and 32%, respectively, and significantly related to the number of LNs removed (p = 0.01). Patients with more than 20 LNs removed and clinical stage I had a significantly lower relapse (p = 0.02). Conclusions Excellent CSS, up to 83% at 15-year, and relatively low risk of recurrence for stage IB NSCLC (8th TNM) patients suggested that AT for those patients could be reserved only for very selected high-risk cases.

  • Serum proteomics profiling identifies a preliminary signature for the diagnosis of early-stage lung cancer
    Roberto Gasparri, Roberta Noberini, Alessandro Cuomo, Avinash Yadav, Davide Tricarico, Carola Salvetto, Patrick Maisonneuve, Valentina Caminiti, Giulia Sedda, Angela Sabalic,et al.
    Wiley
    PURPOSE Lung cancer is the most common cause of death from cancer worldwide, largely due to late diagnosis. Thus, there is an urgent need to develop new approaches to improve the detection of early-stage lung cancer, which would greatly improve patient survival. EXPERIMENTAL DESIGN The quantitative protein expression profiles of microvesicles isolated from the sera from 46 lung cancer patients and 41 high-risk non-cancer subjects were obtained using a mass spectrometry method based on a peptide library matching approach. RESULTS We identified 33 differentially expressed proteins that allow discriminating the two groups. We also built a machine learning model based on serum protein expression profiles that can correctly classify the majority of lung cancer cases and that highlighted a decrease in the levels of Arysulfatase A (ARSA) as the most discriminating factor found in tumors. CONCLUSIONS AND CLINICAL RELEVANCE Our study identified a preliminary, non-invasive protein signature able to discriminate with high specificity and selectivity early-stage lung cancer patients from high-risk healthy subjects. These results provide the basis for future validation studies for the development of a non-invasive diagnostic tool for lung cancer. This article is protected by copyright. All rights reserved.

  • Learning Curve of Robotic Lobectomy for the Treatment of Lung Cancer: How Does It Impact on the Autonomic Nervous System of the Surgeon?
    Antonio Mazzella, Shehab Mohamed, Patrick Maisonneuve, Giulia Sedda, Andrea Cara, Monica Casiraghi, Francesco Petrella, Stefano Maria Donghi, Giorgio Lo Iacono, and Lorenzo Spaggiari
    MDPI AG
    Objective: Our purpose is to define the learning curve for robot-assisted thoracoscopic surgery lobectomy by reporting the experience of a single surgeon. Material and methods: We progressively collected the data concerning the surgical performance of a single male thoracic surgeon, from the beginning of his robotic activity as first operator from January 2021 to June 2022. We evaluated several pre-, intra- and postoperative parameters concerning patients and intraoperative cardiovascular and respiratory outcomes of the surgeon, recorded during surgical interventions, in order to evaluate his cardiovascular stress. We used cumulative sum control charts (CUSUM) to analyze the learning curve. Results: A total of 72 lung lobectomies were performed by a single surgeon in this period. Analyzing the CUSUM of several parameters, the inflection point identifying the transition beyond the surgeon learning phase was reached at cases 28, 22, 27 and 33 when considering operating time, mean heart rate, max heart rate and mean respiratory rate, respectively. Conclusions: The learning curve for robotic lobectomy seems to be safe and feasible with a correct robotic training program. The analysis of a single surgeon from the beginning of his robotic activity demonstrates that confidence, competence, dexterity and security are achieved after about 20–30 procedures, without compromising efficiency and oncological radicality.

  • Artificial Neural Networks in Lung Cancer Research: A Narrative Review
    Elena Prisciandaro, Giulia Sedda, Andrea Cara, Cristina Diotti, Lorenzo Spaggiari, and Luca Bertolaccini
    MDPI AG
    Background: Artificial neural networks are statistical methods that mimic complex neural connections, simulating the learning dynamics of the human brain. They play a fundamental role in clinical decision-making, although their success depends on good integration with clinical protocols. When applied to lung cancer research, artificial neural networks do not aim to be biologically realistic, but rather to provide efficient models for nonlinear regression or classification. Methods: We conducted a comprehensive search of EMBASE (via Ovid), MEDLINE (via PubMed), Cochrane CENTRAL, and Google Scholar from April 2018 to December 2022, using a combination of keywords and related terms for “artificial neural network”, “lung cancer”, “non-small cell lung cancer”, “diagnosis”, and “treatment”. Results: Artificial neural networks have shown excellent aptitude in learning the relationships between the input/output mapping from a given dataset, without any prior information or assumptions about the statistical distribution of the data. They can simultaneously process numerous variables, managing complexity; hence, they have found broad application in tasks requiring attention. Conclusions: Lung cancer is the most common and lethal form of tumor, with limited diagnostic and treatment methods. The advances in tailored medicine have led to the development of novel tools for diagnosis and treatment. Artificial neural networks can provide valuable support for both basic research and clinical decision-making. Therefore, tight cooperation among surgeons, oncologists, and biostatisticians appears mandatory.

  • Surgical management of superior sulcus tumors: A twenty-year experience of an oncological high volume referral centre
    Luca Bertolaccini, Monica Casiraghi, Domenico Galetta, Francesco Petrella, Antonio Mazzella, Giorgio Lo Iacono, Lara Girelli, Claudia Bardoni, Shehab Mohamed, Valeria Musso,et al.
    Frontiers Media SA
    ObjectivesSuperior sulcus tumour, which affects the lung’s apex, is an uncommon subtype of non-small cell lung cancer (NSCLC). The current study examined the clinical characteristics and management of superior sulcus NSCLC patients in a high-volume referral oncological centre over 22 years.MethodsRetrospective review of 100 surgeries with curative intent for superior sulcus NSCLC over 22 years (July 1998 – December 2020). The surgical approach was defined according to the lesion site and the anatomy of the thoracic inlet. Survival curves, including non-cancer-related deaths, were drawn using the Kaplan-Meier methods, and the log-rank test was used to evaluate differences in survival across groups of patients. Cox proportional hazards regression was used to assess the association between selected clinical and pathologic characteristics on OS.Results54 patients received induction treatments. The surgical approach was anterior thoracotomy in 53 patients, Paulson incision in 30, and a combined in 8. The median postoperative length of stay was 11 days (range: 5 – 27 days). Overall 90-day mortality was 6.93%. The median OS was 24.3 months. After a median follow-up of 3 years, 5-year and 10-year OS rates were 33.9% and 26.4%, respectively. A significantly lower 5-year OS was observed in patients with the nodal disease (46.6% in pN0 vs 13.2% in pN+; p = 0.024), without preoperative treatments (41.0% in patients without preoperative treatments versus 17.4%; p = 0.09) and anteriorly located tumour (anterior vs posterior: 17.4% vs 49.1%; p = 0.032). Cox proportional hazards regression showed better survival in the pT1 stage (HR = 4.6; 95% CI: 1.9 – 11.2; p = 0.00076) and in R0 (HR = 4.2; 95% CI: 1.4 – 12.5; p = 0.010).ConclusionsSuperior sulcus tumours still represent a life-threatening condition that, while curable in a significant proportion of cases, requires complex procedures with high surgical risks and a multimodality treatment setting. An optimal surgical approach should be planned to maximise resection completeness and survival. Other factors affecting survival are related to tumour staging, emphasising the importance of a meticulous preoperative workup and candidate selection to identify those expected to benefit from a survival benefit.

  • Real-world survival outcomes of wedge resection versus lobectomy for cT1a/b cN0 cM0 non-small cell lung cancer: a single center retrospective analysis
    Luca Bertolaccini, Andrea Cara, Matteo Chiari, Cristina Diotti, Nimrod Glick, Shehab Mohamed, Clarissa Uslenghi, Antonio Mazzella, Daniela Brambilla, Raffaella Bertolotti,et al.
    Frontiers Media SA
    BackgroundJCOG0802/WJOG4607L showed benefits in overall survival (OS) of segmentectomy. CALGB 140503 confirmed that sublobar resection was not inferior to lobectomy concerning recurrence-free survival (RFS) but did not provide specific OS and RFS according to the techniques of sublobar resections. Hence, we retrospectively analyze the survival differences between wedge resection and lobectomies for stage IA lung cancer.MethodsWe reviewed the clinical records of patients with clinical stage IA NSCLC over 20 years. The inclusion criteria were: preoperative staging with CT scan and whole body CT/PET; tumor size <20 mm; wedge resections or lobectomies with or without lymph node dissection; NSCLC as the only primary tumor during the follow-up period. We excluded: multiple invasive lung cancer; positive resection margin; preoperative evidence of nodal disease; distant metastasis at presentation; follow-up time <5 years. The reverse Kaplan – Meier method estimated the median OS and PFS and compared them by the log-rank test. The stratified backward stepwise Cox regression model was employed for multivariable survival analyses.Results539 patients were identified: 476 (88.3%) lobectomies and 63 (11.7%) wedge resections. The median OS time for the whole cohort was 189.7 months (range: 173.7 – 213.9 months). The 5-year wedge resection and lobectomy OS were 82.2% and 87.0%. The 5-year RFS of wedge resection and lobectomy were 17.8% and 28.9%. The log-rank test showed no significant differences (p = 0.39) between wedge resections and lobectomies regarding OS and RFS (p = 0.23).ConclusionsLobectomy and wedge resection are equivalent oncologic treatments for individuals with cN0/cM0 stage IA NSCLC <20 mm. Validating the current findings requires a prospective, randomized comparison between wedge resection and standard lobectomy to establish the prognostic significance of wedge resection.

  • Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries
    James C Glasbey, Tom EF Abbott, Adesoji Ademuyiwa, Adewale Adisa, Ehab AlAmeer, Sattar Alshryda, Alexis P Arnaud, Brittany Bankhead-Kendall, M K Abou Chaar, Daoud Chaudhry,et al.
    Elsevier BV

  • Volatolomic urinary profile analysis for diagnosis of the early stage of lung cancer
    Roberto Gasparri, Rosamaria Capuano, Alessandra Guaglio, Valentina Caminiti, Federico Canini, Alexandro Catini, Giulia Sedda, Roberto Paolesse, Corrado Di Natale, and Lorenzo Spaggiari
    IOP Publishing
    Abstract Currently, in clinical practice there is a pressing need for potential biomarkers that can identify lung cancer at early stage before becoming symptomatic or detectable by conventional means. Several researchers have independently pointed out that the volatile organic compounds (VOCs) profile can be considered as a lung cancer fingerprint useful for diagnosis. In particular, 16% of volatiles contributing to the human volatilome are found in urine, which is therefore an ideal sample medium. Its analysis through non-invasive, relatively low-cost and straightforward techniques could offer great potential for the early diagnosis of lung cancer. In this study, urinary VOCs were analysed with a gas chromatography-ion mobility spectrometer (GC-IMS) and an electronic nose (e-nose) made by a matrix of twelve quartz microbalances complemented by a photoionization detector. This clinical prospective study involved 127 individuals, divided into two groups: 46 with lung cancer stage I–II–III confirmed by computerized tomography or positron emission tomography—imaging techniques and histology (biopsy), and 81 healthy controls. Both instruments provided a multivariate signal which, after being analysed by a machine learning algorithm, identified eight VOCs that could distinguish lung cancer patients from healthy ones. The eight VOCs are 2-pentanone, 2-hexenal, 2-hexen-1-ol, hept-4-en-2-ol, 2-heptanone, 3-octen-2-one, 4-methylpentanol, 4-methyl-octane. Results show that GC-IMS identifies lung cancer with respect to the control group with a diagnostic accuracy of 88%. Sensitivity resulted as being 85%, and specificity was 90%—Area Under the Receiver Operating Characteristics: 0.91. The contribution made by the e-nose was also important, even though the results were slightly less sensitive with an accuracy of 71.6%. Moreover, of the eight VOCs identified as potential biomarkers, five VOCs had a high sensitivity (p ⩽ 0.06) for early stage (stage I) lung cancer.

  • Pneumonectomy and broncho-pleural fistula: predicting factors and stratification of the risk
    Antonio Mazzella, Luca Bertolaccini, Giulia Sedda, Elena Prisciandaro, Mauro Loi, Giorgio Lo Iacono, and Lorenzo Spaggiari
    Springer Science and Business Media LLC

  • Long-term clinical outcomes and prognostic factors of upfront surgery as a first-line therapy in biopsy-proven clinical N2 non-small cell lung cancer
    Luca Bertolaccini, Elena Prisciandaro, Juliana Guarize, Lara Girelli, Giulia Sedda, Niccolò Filippi, Filippo de Marinis, and Lorenzo Spaggiari
    Frontiers Media SA
    BackgroundMultimodality therapy offers the best opportunity to improve pathological N2 non-small cell lung cancer (NSCLC) prognosis. This paper aimed to evaluate the long-term clinical outcomes and the prognostic factors of upfront surgery as first-line therapy in biopsy-proven clinical N2.MethodsRetrospective review of biopsy-proven cN2 NSCLC patients operated between 2007 and 2017. Upfront surgery was considered if the primary tumour was deemed completely resectable, with mediastinal nodal involvement confined to a single station and no preoperative evidence of extranodal tumour invasion.ResultsTwo hundred eighty-five patients who underwent radical resections were included. One hundred fifty-nine patients (55.8%) received induction chemotherapy. At follow-up completion, 127 (44.6%) patients had died. For the induction chemotherapy group, the median overall survival (OS) was 49 months [95% confidence interval (CI): 38–70 months], and the 5-year OS was 44.4%. The median and 5-year OS for the up front surgery group was 66 months (95% CI: 40–119 months) and 66.3%, respectively. There were no statistically significant differences between treatment approaches (p = 0.48). One hundred thirty-four patients (47.0%) developed recurrence. The recurrence-free survival (RFS) at 5 years was 17% (95% CI: 11–25%) for induction chemotherapy and 22% (95% CI: 9–32%) for upfront surgery; there were no statistically significant differences between groups (p = 0.93). No significant differences were observed based on the clinical N status (OS, p = 0.36; RFS, p = 0.65).ConclusionsUpfront surgery as first-line therapy for biopsy-proven cN2 NSCLC showed favourable clinical outcomes, similar to those obtained after induction chemotherapy followed by surgery. Therefore, it should be considered one of the multimodality treatment options in resectable N2 NSCLC.

  • Long-Term Outcomes of Robotic-Assisted, Video-Assisted and Open Surgery in Non-Small Cell Lung Cancer: A Matched Analysis
    Monica Casiraghi, Alessio Vincenzo Mariolo, Shehab Mohamed, Giulia Sedda, Patrick Maisonneuve, Antonio Mazzella, Giorgio Lo Iacono, Francesco Petrella, and Lorenzo Spaggiari
    MDPI AG
    Introduction: This study makes a comparison between stage I non-small cell lung cancer (NSCLC) patients subjected to either robotic-assisted thoracic surgery (RATS), video-assisted thoracic surgery (VATS) or open thoracotomy, with the aim to evaluate differences between these three approaches in terms of oncological outcomes. Method: We reviewed data from 1367 consecutive patients who, between 2011 and 2017, underwent lobectomy for NSCLC with either open surgery, VATS or RATS, and performed a matched case-control study based on patients’ age, gender, clinical stage (IA, IB) and ASA score. Results: 180 patients (n = 72 RATS, n = 36 VATS, n = 72 open) were analyzed. Complication rates were found to be comparable (72.2% open, 86.1% VATS, 81.9% RATS), with similar grades of severity. The median number of resected lymph nodes was higher in open surgery (n = 22) than in VATS (n = 15; p = 0.0001) and in RATS (n = 17; p = 0.004). Pathological N2 upstaging was higher in open surgery (9.7%) compared to VATS (5.6%) and RATS (5.6%). However, the recurrence rate in VATS was significantly higher than in RATS (log rank p = 0.03). No statistically significant differences were detected in 5-year OS and cancer-specific survival. Conclusions: no differences were found in OS and cancer-specific survival between VATS, RATS and open lobectomy for stage I NSCLC patients; even if in VATS, the incidence of recurrences, in particular local recurrences, was higher than in RATS and in open surgery.

  • Safety Analysis of Salvage Surgery for Advanced Stages or Metastatic Lung Cancers
    Luca Bertolaccini, Domenico Galetta, Giulia Sedda, Filippo de Marinis, and Lorenzo Spaggiari
    Georg Thieme Verlag KG
    AbstractThis case series aimed to analyze the outcomes of patients referred for salvage pulmonary resections after treatment with chemotherapy and immunotherapy for previously metastatic or unresectable tumors.From October 2016, after multidisciplinary board discussion, eight patients (median: 67 years, range: 52–78 years) underwent medical treatment due to advanced-stage diseases (stage cIIIA–cIVa). Four patients underwent cisplatin-based chemotherapy and, due to progression, were moved to an immunotherapy second line (nivolumab: two patients and pembrolizumab: two patients). Instead, four patients underwent combined cisplatin-based chemotherapy and immune checkpoint inhibitors (atezolizumab: two patients and pembrolizumab: two patients). After a multidisciplinary evaluation for salvage surgery, six patients underwent lobectomies, one patient underwent left pneumonectomy, and one patient underwent upper right lobectomy enlarged to the posterior arches of four ribs. The median duration of surgery was 179 minutes (range: 122–246 minutes). At the final pathological stage, three patients showed a complete major response (ypT0 ypN0), one patient was ypT1a ypN0, one ypT3 ypN0, 2 ypT3 ypN1, and one ypT4 ypN0. The hospital length of stay was 6 days (range: 3–23 days). Two patients had a postoperative complication. At the time of follow-up (median: 15.3 months [range: 1–32 months]), six patients were alive without evidence of the recurrence. Two patients died due to recurrence progression (N3 lymph nodes involvement) of the disease after 6 and 32 months.In stage IIIB–IVA nonsmall cell lung cancer, salvage lung surgeries after chemotherapy and immunotherapy are feasible, with high rates of R0 resection. Surgery can be technically tricky without significant morbidity and encouraging outcomes (even with a short-interval follow-up).

  • The Weekday Effect on Morbidity of Lung Cancer Surgery: A Real-World Analysis
    Luca Bertolaccini, Elena Prisciandaro, Giulia Sedda, Giorgio Lo Iacono, Niccolò Filippi, and Lorenzo Spaggiari
    Georg Thieme Verlag KG
    Abstract Background Many authors have investigated the possible adverse effects among patients who underwent elective surgery on Friday when compared with patients operated earlier in the week. Nonetheless, the weekday effect is still a matter of debate. This study aimed at investigating the postoperative morbidity rates after lung cancer surgery and their relationship with the weekday the surgery took place. Materials and Methods We retrospectively reviewed the clinical records of patients who underwent elective thoracotomic lobectomies for lung cancer. Categorical data were analyzed using the chi-square test or Fisher's exact test. Association between predictors and binary outcomes while considering the weekday stratification was determined with Cochran–Mantel–Haenszel statistics. To characterize the typical Friday patient, a multiple logistic regression analysis was performed. Results A total of 817 patients (2015–2019) were identified. Complication rates divided by day of surgery were 164 (20.07%) for patients operated on Mondays, 182 (22.27%) on Tuesdays, 205 (25.09%) on Wednesdays, 172 (21.05%) on Thursdays, and 94 (11.51%) on Fridays. Crude morbidity rates by weekday were Monday 21.53%, Tuesday 20.51%, Wednesday 27.70%, Thursday 20.0%, and Friday 10.26%. No overall association between day of surgery and overall morbidity was found (ρ = 0.095). Median hospital length of stay was 5 days (range: 2–45 days), and there were no statistically significant differences between days. The Cochran–Mantel–Haenszel statistics showed no association between morbidity and the weekday. Conclusion In patients undergoing elective lobectomies for lung cancer, the weekday of surgery was not statistically significantly associated with an increase in the risk of postoperative morbidity.

  • Lung cancer stage distribution from before COVID-19 through 18 months of the pandemic: the experience of a large-volume oncological referral centre
    Luca Bertolaccini, Oriana Ciani, Elena Prisciandaro, Giulia Sedda, and Lorenzo Spaggiari
    Elsevier BV

  • Correction to: Cover always the bronchial stump! A flap could prevent catastrophic complications even in complete broncho‑pleural fistula (Indian Journal of Thoracic and Cardiovascular Surgery, (2022), 10.1007/s12055-022-01386-3)
    Giorgio Lo Iacono, Elena Prisciandaro, Shehab Mohamed, Luca Bertolaccini, Lara Girelli, Giulia Sedda, Antonio Mazzella, Juliana Guarize, Stefano Donghi, and Lorenzo Spaggiari
    Springer Science and Business Media LLC

  • SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study
    GlobalSurg Collaborative Covidsurg Collaborative, Ergin Erginöz, Juan J. Segura-Sampedro and Fardis Vosoughi
    Oxford University Press (OUP)
    Abstract Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results NNVs were more favourable in surgical patients than the general population. The most favourable NNVs were in patients aged 70 years or more needing cancer surgery (351; best case 196, worst case 816) or non-cancer surgery (733; best case 407, worst case 1664). Both exceeded the NNV in the general population (1840; best case 1196, worst case 3066). NNVs for surgical patients remained favourable at a range of SARS-CoV-2 incidence rates in sensitivity analysis modelling. Globally, prioritizing preoperative vaccination of patients needing elective surgery ahead of the general population could prevent an additional 58 687 (best case 115 007, worst case 20 177) COVID-19-related deaths in 1 year. Conclusion As global roll out of SARS-CoV-2 vaccination proceeds, patients needing elective surgery should be prioritized ahead of the general population.

  • Preliminary results of robotic lobectomy in stage iiia-n2 nsclc after induction treatment: A case control study
    Monica Casiraghi, Francesco Petrella, Giulia Sedda, Antonio Mazzella, Juliana Guarize, Patrick Maisonneuve, Filippo De Marinis, and Lorenzo Spaggiari
    MDPI AG
    Despite there already being many studies on robotic surgery as a minimally invasive approach for non-small-cell lung cancer (NSCLC) patients, the use of this technique for stage III disease is still poorly described. These are the preliminary results of our prospective study on the safety and effectiveness of robotic approaches in patients with locally advanced NSCLC in terms of postoperative complications and oncological outcomes. Since 2016, we prospectively investigated 19 consecutive patients with NSCLC stage IIIA-pN2 (diagnosed by EBUS-TBNA) who underwent lobectomy and radical lymph node dissection with robotic approaches after induction treatment. Furthermore, we matched a case-control study with 46 patients treated with open surgery during the same period of time, with similar age, comorbidities, clinical stage and tumor size. The individual matched population was composed of 16 robot-assisted thoracic surgeries and 16 patients who underwent open surgery. The median time range of resection was inferior in the open group compared to robotic lobectomy (243 vs. 161 min; p < 0.001). Lymph node resection and positivity were not significantly different (p = 0.96 and p = 0.57, respectively). Moreover, no difference was observed for PFS (p = 0.16) or OS (p = 0.41). In conclusion, we demonstrated that the early outcomes and oncological results of N2-patients after robotic lobectomy were similar to those who had open surgery. Considering the advantages of minimally invasive surgery, robot-assisted lobectomy appears to be a safe approach to patients with locally advanced diseases.

  • Mos sensors array for the discrimination of lung cancer and at-risk subjects with exhaled breath analysis
    Davide Marzorati, Luca Mainardi, Giulia Sedda, Roberto Gasparri, Lorenzo Spaggiari, and Pietro Cerveri
    MDPI AG
    Lung cancer is characterized by a tremendously high mortality rate and a low 5-year survival rate when diagnosed at a late stage. Early diagnosis of lung cancer drastically reduces its mortality rate and improves survival. Exhaled breath analysis could offer a tool to clinicians to improve the ability to detect lung cancer at an early stage, thus leading to a reduction in the associated survival rate. In this paper, we present an electronic nose for the automatic analysis of exhaled breath. A total of five a-specific gas sensors were embedded in the electronic nose, making it sensitive to different volatile organic compounds (VOCs) contained in exhaled breath. Nine features were extracted from each gas sensor response to exhaled breath, identifying the subject breathprint. We tested the electronic nose on a cohort of 80 subjects, equally split between lung cancer and at-risk control subjects. Including gas sensor features and clinical features in a classification model, recall, precision, and accuracy of 78%, 80%, and 77% were reached using a fourfold cross-validation approach. The addition of other a-specific gas sensors, or of sensors specific to certain compounds, could improve the classification accuracy, therefore allowing for the development of a clinical tool to be integrated in the clinical pipeline for exhaled breath analysis and lung cancer early diagnosis.

  • Clinical prognostic factors in surgically treated oligometastatic non-small cell lung cancer: A systematic review
    Luca Bertolaccini, Monica Casiraghi, Giulia Sedda, Filippo de Marinis, and Lorenzo Spaggiari
    AME Publishing Company

  • Outcomes and Safety Analysis in Superior Vena Cava Resection for Extended Thymic Epithelial Tumors
    Luca Bertolaccini, Elena Prisciandaro, Domenico Galetta, Monica Casiraghi, Juliana Guarize, Francesco Petrella, Giulia Sedda, Giorgio Lo Iacono, Daniela Brambilla, and Lorenzo Spaggiari
    Elsevier BV
    BACKGROUND In stage III-IVa thymic epithelial tumors (TETs), infiltration of superior vena cava (SVC) is not rare. The extent of SVC resection depends on the width of the area of neoplastic invasion. Our paper aims to evaluate the safety and long-term outcomes of extended thymectomy for TETs with SVC resection compared with advanced-stage TETs patients without SVC resection. METHODS Retrospective review of the experience on patients who underwent extended thymectomy for TETs in the last twenty years, according to STROBE methodology. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method. A backward stepwise Cox regression multivariate analysis was performed to determine factors associated with long-term outcomes. RESULTS 78 patients underwent surgery for advanced-stage TETs (Masaoka-Koga stages III-IVa) from January 1998 to April 2019. 14 (17.9%) underwent thymectomy with resection of SVC. Presence of a thymic carcinoma (HR=2.26; 95% CI=1.82-6.18; p=0.038) and the SVC resection (HR=1.89; 95% CI=1.11-3.96; p=0.041) were adverse prognostic factors at multivariate analysis. The median OS and the PFS of all SVC resected patients were 50 (range: 5-207) and 31 months (range: 5-151), respectively. There was no significant difference in OS (p=0.28) and PFS (p=0.32) between SVC resected and not resected patients. CONCLUSIONS SVC resection is a safe and effective procedure to restore the venous system continuity and does not seem to affect survival and disease recurrence. This surgical approach allows radical resection of locally advanced TETs, even after neoadjuvant chemotherapy.

  • A methodological evaluation of the published consensus statements, recommendations and guidelines about surgical management in the course of coronavirus disease pandemic
    Luca Bertolaccini, Giorgio Lo Iacono, Antonio Mazzella, Elena Prisciandaro, Giulia Sedda, and Lorenzo Spaggiari
    SAGE Publications
    Background A project to benchmark the consensus statements, guidelines, and recommendations on surgical management in the course of the COVID-19 pandemic was developed to assess the methodology used. Standard and practical approaches for COVID-19 management in surgical patients to date are not accessible, despite the magnitude of the pandemic. A plethora of consensus statements, guidelines, and recommendations on surgical management in the course of COVID-19 epidemic have been rapidly published in the last three months. Methods Each manuscript was scored on a seven-point scale in the different items and domains with the Appraisal of Guidelines for Research and Evaluation II. Results Nine guidelines that met the inclusion criteria were assessed. Transnational cooperation produced only one guideline. Multivariable analysis showed that improved scores of stakeholders’ involvement were related to internationally developed guidelines. Clarity of presentation was related to the contribution of scientific societies due to greater rigor of development. The rigor of development produced guidelines with a high overall value. Higher healthcare expenses did not produce superior guidelines. Conclusions Evaluated by the Appraisal of Guidelines for Research and Evaluation II, the methodological characteristic of consensus statements, guidelines, and recommendations on surgical management during COVID-19 pandemic was relatively low. International development should be recommended as a model for the development of best methodological quality guidelines.

  • Urinary biomarkers for early diagnosis of lung cancer
    Roberto Gasparri, Giulia Sedda, Valentina Caminiti, Patrick Maisonneuve, Elena Prisciandaro, and Lorenzo Spaggiari
    MDPI AG
    Lung cancer is the leading cause of cancer deaths worldwide. Its early detection has the potential to significantly impact the burden of the disease. The screening and diagnostic techniques in current use suffer from limited specificity. The need therefore arises for a reliable biomarker to identify the disease earlier, which can be integrated into a test. This test would also allow for the recurrence risk after surgery to be stratified. In this context, urine could represent a non-invasive alternative matrix, with the urinary metabolomic profile offering a potential source for the discovery of diagnostic biomarkers. This paper aims to examine the current state of research and the potential for translation into clinical practice.

  • Translational new frontiers in lung cancer research
    Giulia Sedda, Roberto Gasparri, and Lorenzo Spaggiari
    AME Publishing Company
    Lung cancer (LC) accounts for 1.6 million death each year, remaining the leading cause of oncology-related death. This worst-case scenario is linked to poor survival associated with late diagnosis. This happens commonly in clinical practice, even in countries with strong and developed health systems, resulting in a lower chance of survival and a higher cost of treatment. Ideally, screening in an asymptomatic at-risk population could increase the chance of recognition cancerous cells, or even pre-cancerous conditions, in a majority of individuals who will results negative to the test. With this article, we aim to summarize the best new approach in LC research.

RECENT SCHOLAR PUBLICATIONS

  • A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in
    L Bravo, JFF Simes, VR Cardoso, A Adisa, ML Aguilera, A Arnaud, ...
    The Lancet Digital Health 6 (7), e507-e519 2024

  • Integrating artificial intelligence tool in multidisciplinary tumor board for predicting complications after lung cancer surgery
    L Bertolaccini, E Prisciandaro, C Uslenghi, G Maffeis, G Sedda, ...
    European Respiratory Journal 62 (suppl 67) 2023

  • Real-world survival outcomes of wedge resection versus lobectomy for cT1a/b cN0 cM0 non-small cell lung cancer: a single center retrospective analysis
    L Bertolaccini, A Cara, M Chiari, C Diotti, N Glick, S Mohamed, C Uslenghi, ...
    Frontiers in Oncology 13, 1226429 2023

  • Diagnostic Performance and Cell Count of EBUS–TBNA Needle Gauges: A Prospective Trial
    J Guarize, C Diotti, M Casiraghi, S Donghi, C Di Tonno, P Mancuso, ...
    Journal of Clinical Medicine 12 (12), 4033 2023

  • The role of surgery in primary chest wall tumors: over 20 years’ experience in resection and reconstruction
    G Lo Iacono, A Mazzella, S Mohamed, F Petrella, G Sedda, M Casiraghi, ...
    Cancers 15 (7), 2153 2023

  • 92P Predictors, surrogate and patient-reported outcomes in neoadjuvant immunotherapy for lung cancer: A single-center retrospective study
    L Bertolaccini, S Mohamed, D Galetta, F Petrella, M Casiraghi, C Diotti, ...
    Journal of Thoracic Oncology 18 (4), S94-S95 2023

  • Surgically treated pT2aN0M0 (stage IB) non-small cell lung cancer: a 20-year single-center retrospective study
    M Casiraghi, F Petrella, C Bardoni, S Mohamed, G Sedda, J Guarize, ...
    Journal of Clinical Medicine 12 (5), 2081 2023

  • Serum proteomics profiling identifies a preliminary signature for the diagnosis of early‐stage lung cancer
    R Gasparri, R Noberini, A Cuomo, A Yadav, D Tricarico, C Salvetto, ...
    PROTEOMICS–Clinical Applications 17 (2), 2200093 2023

  • Artificial neural networks in lung cancer research: A narrative review
    E Prisciandaro, G Sedda, A Cara, C Diotti, L Spaggiari, L Bertolaccini
    Journal of clinical medicine 12 (3), 880 2023

  • Learning curve of robotic lobectomy for the treatment of lung cancer: how does it impact on the autonomic nervous system of the surgeon?
    A Mazzella, S Mohamed, P Maisonneuve, G Sedda, A Cara, M Casiraghi, ...
    Journal of Personalized Medicine 13 (2), 193 2023

  • Surgical management of superior sulcus tumors: A twenty-year experience of an oncological high volume referral centre
    L Bertolaccini, M Casiraghi, D Galetta, F Petrella, A Mazzella, G Lo Iacono, ...
    Frontiers in Oncology 12, 1080765 2023

  • Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries
    JC Glasbey, TEF Abbott, A Ademuyiwa, A Adisa, E Alameer, S Alshryda, ...
    The Lancet 400 (10363), 1607-1617 2022

  • Volatolomic urinary profile analysis for diagnosis of the early stage of lung cancer
    R Gasparri, R Capuano, A Guaglio, V Caminiti, F Canini, A Catini, ...
    Journal of Breath Research 16 (4), 046008 2022

  • Correction to: Cover always the bronchial stump! A flap could prevent catastrophic complications even in complete broncho‑pleural fistula
    G Lo Iacono, E Prisciandaro, S Mohamed, L Bertolaccini, L Girelli, ...
    Indian Journal of Thoracic and Cardiovascular Surgery, 575-575 2022

  • Correction to: Cover always the bronchial stump! A flap could prevent catastrophic complications even in complete broncho‑pleural fistula
    GL Iacono, E Prisciandaro, S Mohamed, L Bertolaccini, L Girelli, G Sedda, ...
    Indian Journal of Thoracic and Cardiovascular Surgery 38 (5), 575 2022

  • Pneumonectomy and broncho-pleural fistula: Predicting factors and stratification of the risk
    A Mazzella, L Bertolaccini, G Sedda, E Prisciandaro, M Loi, GL Iacono, ...
    Updates in Surgery 74 (4), 1471-1478 2022

  • Long-term clinical outcomes and prognostic factors of upfront surgery as a first-line therapy in biopsy-proven clinical N2 non-small cell lung cancer
    L Bertolaccini, E Prisciandaro, J Guarize, L Girelli, G Sedda, N Filippi, ...
    Frontiers in Oncology 12, 933278 2022

  • Cover always the bronchial stump! A flap could prevent catastrophic complications even in complete broncho-pleural fistula
    GL Iacono, E Prisciandaro, S Mohamed, L Bertolaccini, L Girelli, G Sedda, ...
    Indian Journal of Thoracic and Cardiovascular Surgery 38 (5), 549 2022

  • Long-term outcomes of robotic-assisted, video-assisted and open surgery in non-small cell lung cancer: a matched analysis
    M Casiraghi, AV Mariolo, S Mohamed, G Sedda, P Maisonneuve, ...
    Journal of Clinical Medicine 11 (12), 3363 2022

  • UPFRONT SURGERY AS FIRST-LINE TREATMENT IN PATHOLOGICAL N2 NON-SMALL CELL LUNG CANCER
    L Bertolaccini, E Prisciandaro, G Sedda, L Girelli, L SPAGGIARI
    Chest 161 (6), A315 2022

MOST CITED SCHOLAR PUBLICATIONS

  • Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study
    D Lobo, JM Devys
    Anaesthesia 77 (1), 110 2021
    Citations: 589

  • Volatile signature for the early diagnosis of lung cancer
    R Gasparri, M Santonico, C Valentini, G Sedda, A Borri, F Petrella, ...
    Journal of breath research 10 (1), 016007 2016
    Citations: 157

  • SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study.
    C COVIDSurg, C GlobalSurg
    Anaesthesia 77 (1), 28-39 2022
    Citations: 107

  • A review of exhaled breath: a key role in lung cancer diagnosis
    D Marzorati, L Mainardi, G Sedda, R Gasparri, L Spaggiari, P Cerveri
    Journal of breath research 13 (3), 034001 2019
    Citations: 89

  • SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study
    GS Collaborative, COVIDSurg Collaborative
    The British journal of surgery 108 (9), 1056 2021
    Citations: 57

  • Diagnostic biomarkers for lung cancer prevention
    R Gasparri, R Romano, G Sedda, A Borri, F Petrella, D Galetta, ...
    Journal of breath research 12 (2), 027111 2018
    Citations: 51

  • Effects of pre‐operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study
    COVIDSurg Collaborative, GlobalSurg Collaborative, D Nepogodiev, ...
    Anaesthesia 76 (11), 1454-1464 2021
    Citations: 45

  • Lung cancer surgery in oligometastatic patients: outcome and survival
    M Casiraghi, L Bertolaccini, G Sedda, F Petrella, D Galetta, J Guarize, ...
    European Journal of Cardio-Thoracic Surgery 57 (6), 1173-1180 2020
    Citations: 42

  • Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries
    JC Glasbey, TEF Abbott, A Ademuyiwa, A Adisa, E Alameer, S Alshryda, ...
    The Lancet 400 (10363), 1607-1617 2022
    Citations: 38

  • Volatolomic urinary profile analysis for diagnosis of the early stage of lung cancer
    R Gasparri, R Capuano, A Guaglio, V Caminiti, F Canini, A Catini, ...
    Journal of Breath Research 16 (4), 046008 2022
    Citations: 33

  • MOS sensors array for the discrimination of lung cancer and at-risk subjects with exhaled breath analysis
    D Marzorati, L Mainardi, G Sedda, R Gasparri, L Spaggiari, P Cerveri
    Chemosensors 9 (8), 209 2021
    Citations: 30

  • A brief report on survival after robotic lobectomy for early-stage lung cancer
    L Spaggiari, G Sedda, P Maisonneuve, A Tessitore, M Casiraghi, ...
    Journal of Thoracic Oncology 14 (12), 2176-2180 2019
    Citations: 30

  • Surgery for small cell lung cancer: When and how
    M Casiraghi, G Sedda, E Del Signore, G Piperno, P Maisonneuve, ...
    Lung Cancer 152, 71-77 2021
    Citations: 28

  • Two-step investigation of lung cancer detection by sniffer dogs
    SM Mazzola, F Pirrone, G Sedda, R Gasparri, R Romano, L Spaggiari, ...
    Journal of Breath Research 14 (2), 026011 2020
    Citations: 27

  • A metal oxide gas sensors array for lung cancer diagnosis through exhaled breath analysis
    D Marzorati, L Mainardi, G Sedda, R Gasparri, L Spaggiari, P Cerveri
    2019 41st Annual International Conference of the IEEE Engineering in 2019
    Citations: 27

  • Artificial neural networks in lung cancer research: A narrative review
    E Prisciandaro, G Sedda, A Cara, C Diotti, L Spaggiari, L Bertolaccini
    Journal of clinical medicine 12 (3), 880 2023
    Citations: 25

  • Clinical application of mass spectrometry‐based proteomics in lung cancer early diagnosis
    R Gasparri, G Sedda, R Noberini, T Bonaldi, L Spaggiari
    PROTEOMICS–Clinical Applications 14 (5), 1900138 2020
    Citations: 23

  • The electronic nose’s emerging role in respiratory medicine
    R Gasparri, G Sedda, L Spaggiari
    Sensors 18 (9), 3029 2018
    Citations: 23

  • Non-intubated thoracoscopic lobectomies for lung cancer: an exploratory systematic review and meta-analysis
    E Prisciandaro, L Bertolaccini, G Sedda, L Spaggiari
    Interactive CardioVascular and Thoracic Surgery 31 (4), 499-506 2020
    Citations: 21

  • Paying another tribute to the COVID-19 pandemic: the decrease of early lung cancers
    L Bertolaccini, G Sedda, L Spaggiari
    The Annals of Thoracic Surgery 111 (3), 745 2020
    Citations: 18